395 related articles for article (PubMed ID: 17126522)
21. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.
Furukawa H; Ikuma H; Seki A; Yokoe K; Yuen S; Aramaki T; Yamagushi S
Gut; 2006 Jul; 55(7):1007-11. PubMed ID: 16361308
[TBL] [Abstract][Full Text] [Related]
22. [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review.
Chowdhury FU; Shah N; Scarsbrook AF; Bradley KM
Postgrad Med J; 2010 Mar; 86(1013):174-82. PubMed ID: 20237012
[TBL] [Abstract][Full Text] [Related]
23. FDG-PET/CT in restaging of patients with recurrent breast cancer: possible impact on staging and therapy.
Veit-Haibach P; Antoch G; Beyer T; Stergar H; Schleucher R; Hauth EA; Bockisch A
Br J Radiol; 2007 Jul; 80(955):508-15. PubMed ID: 17537758
[TBL] [Abstract][Full Text] [Related]
24. FDG-PET improves the staging and selection of patients with recurrent colorectal cancer.
Lonneux M; Reffad AM; Detry R; Kartheuser A; Gigot JF; Pauwels S
Eur J Nucl Med Mol Imaging; 2002 Jul; 29(7):915-21. PubMed ID: 12111132
[TBL] [Abstract][Full Text] [Related]
25. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
26. Optimizing the role of FDG PET-CT for potentially operable metastatic colorectal cancer.
Culverwell AD; Chowdhury FU; Scarsbrook AF
Abdom Imaging; 2012 Dec; 37(6):1021-31. PubMed ID: 22371087
[TBL] [Abstract][Full Text] [Related]
27. Additional value of whole-body positron emission tomography with fluorine-18-2-fluoro-2-deoxy-D-glucose in recurrent colorectal cancer.
Flamen P; Stroobants S; Van Cutsem E; Dupont P; Bormans G; De Vadder N; Penninckx F; Van Hoe L; Mortelmans L
J Clin Oncol; 1999 Mar; 17(3):894-901. PubMed ID: 10071281
[TBL] [Abstract][Full Text] [Related]
28. Ovarian cancer recurrence: role of whole-body positron emission tomography using 2-[fluorine-18]-fluoro-2-deoxy- D-glucose.
Torizuka T; Nobezawa S; Kanno T; Futatsubashi M; Yoshikawa E; Okada H; Takekuma M; Maeda M; Ouchi Y
Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):797-803. PubMed ID: 12029554
[TBL] [Abstract][Full Text] [Related]
29. The clinical application of positron emission tomography to colorectal cancer management.
Arulampalam TH; Costa DC; Bomanji JB; Ell PJ
Q J Nucl Med; 2001 Sep; 45(3):215-30. PubMed ID: 11788814
[TBL] [Abstract][Full Text] [Related]
30. Staging pathways in recurrent colorectal carcinoma: is contrast-enhanced 18F-FDG PET/CT the diagnostic tool of choice?
Soyka JD; Veit-Haibach P; Strobel K; Breitenstein S; Tschopp A; Mende KA; Lago MP; Hany TF
J Nucl Med; 2008 Mar; 49(3):354-61. PubMed ID: 18287263
[TBL] [Abstract][Full Text] [Related]
31. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
[TBL] [Abstract][Full Text] [Related]
32. Diagnostic accuracy of serial CT/magnetic resonance imaging review vs. positron emission tomography/CT in colorectal cancer patients with suspected and known recurrence.
Potter KC; Husband JE; Houghton SL; Thomas K; Brown G
Dis Colon Rectum; 2009 Feb; 52(2):253-9. PubMed ID: 19279420
[TBL] [Abstract][Full Text] [Related]
33. Positron emission tomography/computerized tomography functional imaging of esophageal and colorectal cancer.
Larson SM; Schoder H; Yeung H
Cancer J; 2004; 10(4):243-50. PubMed ID: 15383205
[TBL] [Abstract][Full Text] [Related]
34. The clinical impact of camera-based positron emission tomography imaging in patients with recurrent colorectal cancer.
Miller E; Lerman H; Gutman M; Figer A; Livshitz G; Even-Sapir E
Invest Radiol; 2004 Jan; 39(1):8-12. PubMed ID: 14701983
[TBL] [Abstract][Full Text] [Related]
35. [[18F]-FDG-PET in the diagnostics of gastrointestinal tumors].
Buchmann I; Ganten TM; Haberkorn U
Z Gastroenterol; 2008 Apr; 46(4):367-75. PubMed ID: 18393156
[TBL] [Abstract][Full Text] [Related]
36. [Combined FDG PET/CT imaging for restaging of colorectal cancer patients: impact of image fusion on staging accuracy].
Strunk H; Bucerius J; Jaeger U; Joe A; Flacke S; Reinhardt M; Hortling N; Palmedo H
Rofo; 2005 Sep; 177(9):1235-41. PubMed ID: 16123869
[TBL] [Abstract][Full Text] [Related]
37. Clarifying the diagnosis of clinically suspected recurrence of cervical cancer: impact of 18F-FDG PET.
van der Veldt AA; Buist MR; van Baal MW; Comans EF; Hoekstra OS; Molthoff CF
J Nucl Med; 2008 Dec; 49(12):1936-43. PubMed ID: 18997039
[TBL] [Abstract][Full Text] [Related]
38. Clinical use of combined positron emission tomography and computed tomography (FDG-PET/CT) in recurrent ovarian cancer.
Thrall MM; DeLoia JA; Gallion H; Avril N
Gynecol Oncol; 2007 Apr; 105(1):17-22. PubMed ID: 17208284
[TBL] [Abstract][Full Text] [Related]
39. Value of fluorodeoxyglucose positron emission tomography in women with breast cancer.
Landheer ML; Steffens MG; Klinkenbijl JH; Westenberg AH; Oyen WJ
Br J Surg; 2005 Nov; 92(11):1363-7. PubMed ID: 16187254
[TBL] [Abstract][Full Text] [Related]
40. Value of 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent colorectal cancer.
Hung GU; Shiau YC; Tsai SC; Chao TH; Ho YJ; Kao CH
Anticancer Res; 2001; 21(2B):1375-8. PubMed ID: 11396217
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]